Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 24Terminated 18Withdrawn 4Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Plasma cell 1Lymphoid 1

Conditions

Recurrence 2Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Panobinostat × Clear all
NCT03632317 2019-08-19

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

University of Michigan Rogel Cancer Center

Phase 2 Withdrawn
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT01115036 2013-06-19

CLBH589C

Duke University

Phase 2 Withdrawn
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡